Compare Sana Biotechnology Inc (SANA) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Valero Energy Corporation — how do they compare? Sana Biotechnology Inc trades at $2.81 (market cap $836.71M), while Valero Energy Corporation trades at $435.29 (market cap $127.78B). The key difference: Valero Energy Corporation is far larger — about 152.7× Sana Biotechnology Inc's market cap, and Valero Energy Corporation pays a 1.08% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Valero Energy Corporation for 56 Days on average.
| SANA | VLO | |
|---|---|---|
Market Cap | $836.71M | $127.78B |
Volume | 4,507,444 | 2,570,225 |
Sector | Health | Energy |
52-Week High | $5.92 | $443.80 |
52-Week Low | $2.68 | $156.39 |
Typical Hold Time | 23 Days | 56 Days |
Enterprise Value | $749.96M | $131.26B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Valero Energy (VLO) trades at $441.93, up 4.2% today, near its 52-week high with strong bullish momentum from moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 expected at $20.17 EPS. Revenue declined to $122.69B in 2025, but net income margin improved to 5.17%, supported by a robust ROE of 29.31%. Analyst consensus is bullish with a $408.10 price target, though RSI levels indicate overbought conditions.
VLO's outlook is positive due to refining margin strength and earnings beats, but risks include volatile energy prices and potential policy impacts like diesel export bans. The stock offers growth potential with a reasonable P/E of 18.51, yet high valuation multiples and technical overbought signals warrant caution for near-term entries.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
